Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: human plasma-derived biologics - Abeona Therapeutics

Drug Profile

Research programme: human plasma-derived biologics - Abeona Therapeutics

Alternative Names: A1PI - Abeona Therapeutics; AAT - Abeona Therapeutics; AHF - Abeona Therapeutics; Alpha-1 protease inhibitor - Abeona Therapeutics; Antihaemophilic factor VIII - Abeona Therapeutics; Coagulation factors - Abeona Therapeutics; Human plasma-derived therapeutics - Abeona Therapeutics; IVIG - Abeona Therapeutics; Protein biologic therapeutics - Abeona Therapeutics; PTB-101 SDF Alpha™; PTB-201 SDF IVIG™; SDF Alpha™; SDF Gamma™

Latest Information Update: 24 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PlasmaTech Biopharmaceuticals
  • Developer Abeona Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Blood coagulation factors; Blood proteins; Enzymes; Glycoproteins; Immunoglobulins; Immunoproteins; Secretory proteinase inhibitory proteins; Serum globulins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Factor VIII stimulants; Immunoglobulin stimulants; Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alpha 1-antitrypsin deficiency; Autoimmune disorders; Blood coagulation disorders; Chronic obstructive pulmonary disease; Haemophilia A; Immunocompromised infections

Most Recent Events

  • 24 May 2018 Discontinued - Preclinical for Autoimmune disorders in USA (IV)
  • 24 May 2018 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Parenteral)
  • 24 May 2018 Discontinued - Preclinical for Immunocompromised infections in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top